Foundation for Angelman Syndrome Therapeutics

Home
United States
Austin, TX
Foundation for Angelman Syndrome Therapeutics

FAST is the leading patient advocacy organization working to cure Angelman syndrome. We are based in the USA with 9 global chapters around the world.
(205)

Page Rules:
Thank you for your interest in the Foundation for Angelman Syndrome Therapeutics (FAST). FAST was founded with a single, critical mission: to cure Angelman syndrome. The organization, founded in 2008, is the largest non-governmental funder of Angelman syndrome research, and today has a global presence. We designed this page as a platform to share research, resources, and information to our Angelman syndrome community and those interested in supporting our mission to cure AS. We have outlined community guidelines to ensure that conversations remain respectful and are aligned to Facebook’s official terms of use and community standards. FAST reserves the right to modify the guidelines, if needed. Your acceptance of these terms is made by the use of this page. To ensure that this page remains a positive resource, we have developed the following page rules. These rules are guidelines for comments on our page, and we reserve the right to delete any comments or threads that violate these rules:

1. Be kind and courteous. We're all in this together to create a positive, informative, and respectful environment. Healthy debates are natural, but kindness is required.

2. No disrespectful comments. Bullying of any kind isn't allowed and degrading comments will not be tolerated. Do not post profane, defamatory, offensive or violent language.

3. Do not share personal and private information. This is a public page and information that is shared will be publicly accessible.

4. No advertising. Don’t use this page for advertising your or someone else’s business, page or website.

5. Do not disclose confidential, nonpublic or proprietary business information that may compromise the confidentiality and security of FAST or any other person or company.

6. Do not post attacks or negative comments regarding groups. Any comments meant to harass, disparage, threaten or abuse an individual will be removed. FAST will do its best to respond to any questions or concerns in a timely fashion; however, at times, FAST may choose to respond privately or not to respond at all.

03/06/2026

In case you missed the CNBC Cures livestream on Tuesday, you can watch Dr. Allyson Berent and Mike Hanrahan talk about why FAST exists and what our venture philanthropy model is really built to do: not just fund research, but push the work forward with urgency and discipline, so progress can reach our loved ones.

Watch the recording: https://buff.ly/HtOaSc0

03/05/2026

Big news: Team Kick-AS is heading to the 2026 TCS New York City Marathon! 🗽🏃

We’re thrilled to share that for the first time ever, FAST is an official charity partner of this iconic race! We have a very limited number of bibs available--first-come, first-serve--and would love for you join Team Kick-AS to run the five Boroughs with us!

If you secured a bib through the official New York Road Runners drawing, this is the perfect opportunity to dedicate your miles to raising critical funds for Angelman syndrome research.

Learn more and join Team Kick-AS: https://buff.ly/LDmPA8p

03/04/2026

Today marks our 3rd AS Congressional Advocacy Day, where over 150 Angelman advocates take to Capitol Hill to meet with their elected officials. Through personal stories and a united voice, they are having meaningful conversations and making specific legislative requests to ensure Angelman syndrome remains a priority in the U.S. Congress – a federal effort!

JOIN US: We urge families, friends, researchers, and clinicians to amplify our voices by reaching out to your congressional leaders in support of the in-person advocacy happening right now on Capitol Hill!

Take action in 4 easy step to send the same united message to your elected officials:
1️⃣https://bit.ly/2026advocacydayasks
2️⃣Enter your address
3️⃣Put your name, relationship to AS and address in the closing
4️⃣Click “Send It!”

Our 2026 priorities include:
• Asking the Department of Defense (DOD) to continue to include Angelman syndrome as an eligible condition for funding,
• While urging FDA and NIH to prioritize and fund patient-informed, gene-targeted, and real‑world data efforts that accelerate development and evaluation of Angelman therapies

03/03/2026

This is a big week for Angelman syndrome patient-led advocacy.

Today in NYC, FAST leaders Dr. Allyson Berent and Mike Hanrahan will join Becky Quick at the CNBC Cures Summit to discuss the evolving role of patient-led advocacy in rare disease.

Also today in Washington, DC, FAST and ASF are gearing up for Congressional Advocacy Day with a simple goal: show up with voices from across the country, build relationships with congressional offices, and turn more lawmakers into champions for Angelman syndrome.

Different rooms, same goal: making sure families are part of the decisions that shape research, regulation, and access.

03/02/2026

Tomorrow, FAST will join one of the most important rare disease conversations happening this year.

The first-ever CNBC Cures Summit is bringing together leaders across biotech, investment, and policy to focus on what it will take to accelerate the future of medicine in rare disease.

FAST leaders Dr. Allyson Berent and Mike Hanrahan will join Becky Quick for a featured conversation, From Awareness to Action, on how FAST’s venture philanthropy model has helped move beyond awareness to actively fund, coordinate, and accelerate research and clinical development in Angelman syndrome.

FAST will bring a patient- and family-led perspective grounded in ex*****on: the outcomes, shared tools, and trial readiness that help reduce friction and move therapeutic development forward.

Register to watch the free livestream: https://bit.ly/4cinix3

02/28/2026

International Angelman Day 2026 was powered by YOU! 💙

Thank you for sharing your stories, raising your voices, lighting landmarks blue, and helping the world see what life with Angelman syndrome really looks like. Because of this community, these stories traveled farther than we imagined.

See the media moments, the blue landmarks, and what we can build together next:
https://cureangelman.org/articles/international-angelman-day-2026-community-impact

02/27/2026

Congratulations to longtime FAST collaborator Dr. David Segal on being named Chair of the Department of Biochemistry and Molecular Medicine at UC Davis School of Medicine.

For more than a decade, Dr. Segal and his lab at the UC Davis MIND Institute have been key partners in FAST-funded Angelman syndrome research, including advancing our understanding of genetic mechanisms and helping drive innovative, gene-targeted therapeutic approaches.

Read full announcement: https://buff.ly/DIo01j3

02/24/2026

The first-ever CNBC Cures Summit on March 3 will spotlight conversations focused on accelerating the future of medicine through breakthroughs in rare disease research.

Dr. Allyson Berent, FAST's chief science officer and co-founder of AS2Bio, and Mike Hanrahan, entrepreneur, investor and vice chair of FAST’s board of directors, will join Becky Quick to discuss FAST's venture-philanthropy model and how patients have remained at the center of the work being done.

Learn more and register for the livestream: https://bit.ly/4cinix3

02/19/2026

For two decades, the Angelman Syndrome Natural History Study has been building data that drives discovery.

Thanks to the dedication of clinicians, researchers, coordinator, individuals with Angelman syndrome, and their families, the AS Natural History Study has become a beacon of progress.

ASF and FAST are proud to celebrate this milestone with the Natural History Study team and the community that made it happen.

If you are interested in participating in the AS Natural History Study, click here to learn more: https://buff.ly/G61us1u

02/15/2026

Celebrate International Angelman Day with FAST!

Around the world, families, researchers, advocates, and partners are raising awareness of Angelman syndrome and pushing research forward. This day reflects the strength of a global community united by progress, persistence, and shared purpose.

Thank you to our global partners and affiliates for showing up and helping make Angelman syndrome visible today and every day.

If you’re able, consider making a donation to support the research moving this field forward. Every gift helps sustain momentum behind the science and the community driving it.

Donate here: https://buff.ly/jp19Xqc

02/14/2026

When Elizabeth O’Connor talks about Angelman syndrome, you feel both the love and the urgency. 💙

As Ryan’s mom, she’s living it. As FAST’s Philanthropy Manager, she’s helping push the work forward.

In her Fox 32 Chicago interview for International Angelman Day, Elizabeth shares what families carry every day with Angelman syndrome, and why they keep fighting: there is real momentum in the science. FAST is building that momentum by funding and accelerating the most promising research toward potential treatments.

Watch Elizabeth's interview and if she inspires you, please consider making a donation to help FAST fuel the research families are counting on. www.cureangelman.org/give

02/14/2026

In rare disease, “promising” isn’t enough.

The gap between an idea and a therapy is long, expensive, and full of unglamorous steps that still have to happen: the studies, the manufacturing work, the regulatory prep, the trial readiness. If that funding disappears, momentum slows, and families are left waiting.

That’s why patient organizations and families step in. Not because it’s easy, but because time matters.

If you want to help move Angelman syndrome research forward, a donation is a direct way to keep progress moving: https://buff.ly/jp19Xqc

Address

Austin, TX

Telephone

+16308503278

Website

http://www.cureangelman.org/

Alerts

Be the first to know and let us send you an email when Foundation for Angelman Syndrome Therapeutics posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.